Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors
The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing c...
Gespeichert in:
Veröffentlicht in: | Clinical and vaccine immunology 2015-07, Vol.22 (7), p.726-741 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 741 |
---|---|
container_issue | 7 |
container_start_page | 726 |
container_title | Clinical and vaccine immunology |
container_volume | 22 |
creator | Hart, Bryan E Asrican, Rose Lim, So-Yon Sixsmith, Jaimie D Lukose, Regy Souther, Sommer J R Rayasam, Swati D G Saelens, Joseph W Chen, Ching-Ju Seay, Sarah A Berney-Meyer, Linda Magtanong, Leslie Vermeul, Kim Pajanirassa, Priyadharshini Jimenez, Amanda E Ng, Tony W Tobin, David M Porcelli, Steven A Larsen, Michelle H Schmitz, Joern E Haynes, Barton F Jacobs, Jr, William R Lee, Sunhee Frothingham, Richard |
description | The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing consistent insert expression has encountered challenges in stability. Here, we describe a method for the development of large recombinant BCG accession lots which stably express the lentiviral antigens, human immunodeficiency virus (HIV) gp120 and simian immunodeficiency virus (SIV) Gag, using selectable leucine auxotrophic complementation. Successful establishment of vaccine stability stems from stringent quality control criteria which not only screen for highly stable complemented BCG ΔleuCD transformants but also thoroughly characterize postproduction quality. These parameters include consistent production of correctly sized antigen, retention of sequence-pure plasmid DNA, freeze-thaw recovery, enumeration of CFU, and assessment of cellular aggregates. Importantly, these quality assurance procedures were indicative of overall vaccine stability, were predictive for successful antigen expression in subsequent passaging both in vitro and in vivo, and correlated with induction of immune responses in murine models. This study has yielded a quality-controlled BCG ΔleuCD vaccine expressing HIV gp120 that retained stable full-length expression after 10(24)-fold amplification in vitro and following 60 days of growth in mice. A second vaccine lot expressed full-length SIV Gag for >10(68)-fold amplification in vitro and induced potent antigen-specific T cell populations in vaccinated mice. Production of large, well-defined recombinant BCG ΔleuCD lots can allow confidence that vaccine materials for immunogenicity and protection studies are not negatively affected by instability or differences between freshly grown production batches. |
doi_str_mv | 10.1128/CVI.00075-15 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4478521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1701493795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-5499288ec7073eaef7b9c84cdb2b450a82948070e1d297891e5dab8e0640abd13</originalsourceid><addsrcrecordid>eNqFkUtr3DAURkVJaR7tLuugZRZ1ItmSJW0KiZk8YEpJmoTuhCTfSRVsayLJQ-ffx5MX7aqre-EePu7HQWifkiNKS3nc3F0eEUIELyj_gHYo53VRC_Vr622XlG6j3ZQeCGFVLcUntF1yVTJR1zvo4Wc2tgM8-7OMkJIPAw4LPIch-5WPpsMn03YPQ8J2ja9G0_m8Lpow5Bi6Dlp8DS701g9myPj72gVrXIboxx7bsPIJnzbn-A5cDjF9Rh8Xpkvw5XXuoduz2U1zUcx_nF82J_PCMSpywZlSpZTgBBEVGFgIq5xkrrWlZZwYWSomiSBA21IJqSjw1lgJpGbE2JZWe-jbS-5ytD20buoyFdHL6HsT1zoYr_-9DP63vg8rzZiQvNwEHL4GxPA4Qsq698lB15kBwpg0FYQyVQnF_4_WanI0NSET-vUFdTGkFGHx_hElemNSTyb1s0lNN8kHf7d4h9_UVU9hS5sZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1691287070</pqid></control><display><type>article</type><title>Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors</title><source>American Society for Microbiology</source><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Hart, Bryan E ; Asrican, Rose ; Lim, So-Yon ; Sixsmith, Jaimie D ; Lukose, Regy ; Souther, Sommer J R ; Rayasam, Swati D G ; Saelens, Joseph W ; Chen, Ching-Ju ; Seay, Sarah A ; Berney-Meyer, Linda ; Magtanong, Leslie ; Vermeul, Kim ; Pajanirassa, Priyadharshini ; Jimenez, Amanda E ; Ng, Tony W ; Tobin, David M ; Porcelli, Steven A ; Larsen, Michelle H ; Schmitz, Joern E ; Haynes, Barton F ; Jacobs, Jr, William R ; Lee, Sunhee ; Frothingham, Richard</creator><creatorcontrib>Hart, Bryan E ; Asrican, Rose ; Lim, So-Yon ; Sixsmith, Jaimie D ; Lukose, Regy ; Souther, Sommer J R ; Rayasam, Swati D G ; Saelens, Joseph W ; Chen, Ching-Ju ; Seay, Sarah A ; Berney-Meyer, Linda ; Magtanong, Leslie ; Vermeul, Kim ; Pajanirassa, Priyadharshini ; Jimenez, Amanda E ; Ng, Tony W ; Tobin, David M ; Porcelli, Steven A ; Larsen, Michelle H ; Schmitz, Joern E ; Haynes, Barton F ; Jacobs, Jr, William R ; Lee, Sunhee ; Frothingham, Richard</creatorcontrib><description>The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing consistent insert expression has encountered challenges in stability. Here, we describe a method for the development of large recombinant BCG accession lots which stably express the lentiviral antigens, human immunodeficiency virus (HIV) gp120 and simian immunodeficiency virus (SIV) Gag, using selectable leucine auxotrophic complementation. Successful establishment of vaccine stability stems from stringent quality control criteria which not only screen for highly stable complemented BCG ΔleuCD transformants but also thoroughly characterize postproduction quality. These parameters include consistent production of correctly sized antigen, retention of sequence-pure plasmid DNA, freeze-thaw recovery, enumeration of CFU, and assessment of cellular aggregates. Importantly, these quality assurance procedures were indicative of overall vaccine stability, were predictive for successful antigen expression in subsequent passaging both in vitro and in vivo, and correlated with induction of immune responses in murine models. This study has yielded a quality-controlled BCG ΔleuCD vaccine expressing HIV gp120 that retained stable full-length expression after 10(24)-fold amplification in vitro and following 60 days of growth in mice. A second vaccine lot expressed full-length SIV Gag for >10(68)-fold amplification in vitro and induced potent antigen-specific T cell populations in vaccinated mice. Production of large, well-defined recombinant BCG ΔleuCD lots can allow confidence that vaccine materials for immunogenicity and protection studies are not negatively affected by instability or differences between freshly grown production batches.</description><identifier>ISSN: 1556-6811</identifier><identifier>ISSN: 1556-679X</identifier><identifier>EISSN: 1556-679X</identifier><identifier>DOI: 10.1128/CVI.00075-15</identifier><identifier>PMID: 25924766</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>AIDS Vaccines - genetics ; AIDS Vaccines - immunology ; Animals ; Antigens, Viral - biosynthesis ; Antigens, Viral - genetics ; Drug Carriers ; Gene Products, gag - biosynthesis ; Gene Products, gag - genetics ; Genetic Vectors ; Genomic Instability ; HIV Envelope Protein gp120 - biosynthesis ; HIV Envelope Protein gp120 - genetics ; Human immunodeficiency virus ; Mice, Inbred C57BL ; Mycobacterium bovis ; Mycobacterium bovis - genetics ; SAIDS Vaccines - genetics ; SAIDS Vaccines - immunology ; Simian immunodeficiency virus ; T-Lymphocytes - immunology ; Vaccines</subject><ispartof>Clinical and vaccine immunology, 2015-07, Vol.22 (7), p.726-741</ispartof><rights>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</rights><rights>Copyright © 2015, American Society for Microbiology. All Rights Reserved. 2015 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-5499288ec7073eaef7b9c84cdb2b450a82948070e1d297891e5dab8e0640abd13</citedby><cites>FETCH-LOGICAL-c417t-5499288ec7073eaef7b9c84cdb2b450a82948070e1d297891e5dab8e0640abd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478521/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478521/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,3175,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25924766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hart, Bryan E</creatorcontrib><creatorcontrib>Asrican, Rose</creatorcontrib><creatorcontrib>Lim, So-Yon</creatorcontrib><creatorcontrib>Sixsmith, Jaimie D</creatorcontrib><creatorcontrib>Lukose, Regy</creatorcontrib><creatorcontrib>Souther, Sommer J R</creatorcontrib><creatorcontrib>Rayasam, Swati D G</creatorcontrib><creatorcontrib>Saelens, Joseph W</creatorcontrib><creatorcontrib>Chen, Ching-Ju</creatorcontrib><creatorcontrib>Seay, Sarah A</creatorcontrib><creatorcontrib>Berney-Meyer, Linda</creatorcontrib><creatorcontrib>Magtanong, Leslie</creatorcontrib><creatorcontrib>Vermeul, Kim</creatorcontrib><creatorcontrib>Pajanirassa, Priyadharshini</creatorcontrib><creatorcontrib>Jimenez, Amanda E</creatorcontrib><creatorcontrib>Ng, Tony W</creatorcontrib><creatorcontrib>Tobin, David M</creatorcontrib><creatorcontrib>Porcelli, Steven A</creatorcontrib><creatorcontrib>Larsen, Michelle H</creatorcontrib><creatorcontrib>Schmitz, Joern E</creatorcontrib><creatorcontrib>Haynes, Barton F</creatorcontrib><creatorcontrib>Jacobs, Jr, William R</creatorcontrib><creatorcontrib>Lee, Sunhee</creatorcontrib><creatorcontrib>Frothingham, Richard</creatorcontrib><title>Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors</title><title>Clinical and vaccine immunology</title><addtitle>Clin Vaccine Immunol</addtitle><description>The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing consistent insert expression has encountered challenges in stability. Here, we describe a method for the development of large recombinant BCG accession lots which stably express the lentiviral antigens, human immunodeficiency virus (HIV) gp120 and simian immunodeficiency virus (SIV) Gag, using selectable leucine auxotrophic complementation. Successful establishment of vaccine stability stems from stringent quality control criteria which not only screen for highly stable complemented BCG ΔleuCD transformants but also thoroughly characterize postproduction quality. These parameters include consistent production of correctly sized antigen, retention of sequence-pure plasmid DNA, freeze-thaw recovery, enumeration of CFU, and assessment of cellular aggregates. Importantly, these quality assurance procedures were indicative of overall vaccine stability, were predictive for successful antigen expression in subsequent passaging both in vitro and in vivo, and correlated with induction of immune responses in murine models. This study has yielded a quality-controlled BCG ΔleuCD vaccine expressing HIV gp120 that retained stable full-length expression after 10(24)-fold amplification in vitro and following 60 days of growth in mice. A second vaccine lot expressed full-length SIV Gag for >10(68)-fold amplification in vitro and induced potent antigen-specific T cell populations in vaccinated mice. Production of large, well-defined recombinant BCG ΔleuCD lots can allow confidence that vaccine materials for immunogenicity and protection studies are not negatively affected by instability or differences between freshly grown production batches.</description><subject>AIDS Vaccines - genetics</subject><subject>AIDS Vaccines - immunology</subject><subject>Animals</subject><subject>Antigens, Viral - biosynthesis</subject><subject>Antigens, Viral - genetics</subject><subject>Drug Carriers</subject><subject>Gene Products, gag - biosynthesis</subject><subject>Gene Products, gag - genetics</subject><subject>Genetic Vectors</subject><subject>Genomic Instability</subject><subject>HIV Envelope Protein gp120 - biosynthesis</subject><subject>HIV Envelope Protein gp120 - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Mice, Inbred C57BL</subject><subject>Mycobacterium bovis</subject><subject>Mycobacterium bovis - genetics</subject><subject>SAIDS Vaccines - genetics</subject><subject>SAIDS Vaccines - immunology</subject><subject>Simian immunodeficiency virus</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccines</subject><issn>1556-6811</issn><issn>1556-679X</issn><issn>1556-679X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtr3DAURkVJaR7tLuugZRZ1ItmSJW0KiZk8YEpJmoTuhCTfSRVsayLJQ-ffx5MX7aqre-EePu7HQWifkiNKS3nc3F0eEUIELyj_gHYo53VRC_Vr622XlG6j3ZQeCGFVLcUntF1yVTJR1zvo4Wc2tgM8-7OMkJIPAw4LPIch-5WPpsMn03YPQ8J2ja9G0_m8Lpow5Bi6Dlp8DS701g9myPj72gVrXIboxx7bsPIJnzbn-A5cDjF9Rh8Xpkvw5XXuoduz2U1zUcx_nF82J_PCMSpywZlSpZTgBBEVGFgIq5xkrrWlZZwYWSomiSBA21IJqSjw1lgJpGbE2JZWe-jbS-5ytD20buoyFdHL6HsT1zoYr_-9DP63vg8rzZiQvNwEHL4GxPA4Qsq698lB15kBwpg0FYQyVQnF_4_WanI0NSET-vUFdTGkFGHx_hElemNSTyb1s0lNN8kHf7d4h9_UVU9hS5sZ</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Hart, Bryan E</creator><creator>Asrican, Rose</creator><creator>Lim, So-Yon</creator><creator>Sixsmith, Jaimie D</creator><creator>Lukose, Regy</creator><creator>Souther, Sommer J R</creator><creator>Rayasam, Swati D G</creator><creator>Saelens, Joseph W</creator><creator>Chen, Ching-Ju</creator><creator>Seay, Sarah A</creator><creator>Berney-Meyer, Linda</creator><creator>Magtanong, Leslie</creator><creator>Vermeul, Kim</creator><creator>Pajanirassa, Priyadharshini</creator><creator>Jimenez, Amanda E</creator><creator>Ng, Tony W</creator><creator>Tobin, David M</creator><creator>Porcelli, Steven A</creator><creator>Larsen, Michelle H</creator><creator>Schmitz, Joern E</creator><creator>Haynes, Barton F</creator><creator>Jacobs, Jr, William R</creator><creator>Lee, Sunhee</creator><creator>Frothingham, Richard</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7T5</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20150701</creationdate><title>Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors</title><author>Hart, Bryan E ; Asrican, Rose ; Lim, So-Yon ; Sixsmith, Jaimie D ; Lukose, Regy ; Souther, Sommer J R ; Rayasam, Swati D G ; Saelens, Joseph W ; Chen, Ching-Ju ; Seay, Sarah A ; Berney-Meyer, Linda ; Magtanong, Leslie ; Vermeul, Kim ; Pajanirassa, Priyadharshini ; Jimenez, Amanda E ; Ng, Tony W ; Tobin, David M ; Porcelli, Steven A ; Larsen, Michelle H ; Schmitz, Joern E ; Haynes, Barton F ; Jacobs, Jr, William R ; Lee, Sunhee ; Frothingham, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-5499288ec7073eaef7b9c84cdb2b450a82948070e1d297891e5dab8e0640abd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>AIDS Vaccines - genetics</topic><topic>AIDS Vaccines - immunology</topic><topic>Animals</topic><topic>Antigens, Viral - biosynthesis</topic><topic>Antigens, Viral - genetics</topic><topic>Drug Carriers</topic><topic>Gene Products, gag - biosynthesis</topic><topic>Gene Products, gag - genetics</topic><topic>Genetic Vectors</topic><topic>Genomic Instability</topic><topic>HIV Envelope Protein gp120 - biosynthesis</topic><topic>HIV Envelope Protein gp120 - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Mice, Inbred C57BL</topic><topic>Mycobacterium bovis</topic><topic>Mycobacterium bovis - genetics</topic><topic>SAIDS Vaccines - genetics</topic><topic>SAIDS Vaccines - immunology</topic><topic>Simian immunodeficiency virus</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hart, Bryan E</creatorcontrib><creatorcontrib>Asrican, Rose</creatorcontrib><creatorcontrib>Lim, So-Yon</creatorcontrib><creatorcontrib>Sixsmith, Jaimie D</creatorcontrib><creatorcontrib>Lukose, Regy</creatorcontrib><creatorcontrib>Souther, Sommer J R</creatorcontrib><creatorcontrib>Rayasam, Swati D G</creatorcontrib><creatorcontrib>Saelens, Joseph W</creatorcontrib><creatorcontrib>Chen, Ching-Ju</creatorcontrib><creatorcontrib>Seay, Sarah A</creatorcontrib><creatorcontrib>Berney-Meyer, Linda</creatorcontrib><creatorcontrib>Magtanong, Leslie</creatorcontrib><creatorcontrib>Vermeul, Kim</creatorcontrib><creatorcontrib>Pajanirassa, Priyadharshini</creatorcontrib><creatorcontrib>Jimenez, Amanda E</creatorcontrib><creatorcontrib>Ng, Tony W</creatorcontrib><creatorcontrib>Tobin, David M</creatorcontrib><creatorcontrib>Porcelli, Steven A</creatorcontrib><creatorcontrib>Larsen, Michelle H</creatorcontrib><creatorcontrib>Schmitz, Joern E</creatorcontrib><creatorcontrib>Haynes, Barton F</creatorcontrib><creatorcontrib>Jacobs, Jr, William R</creatorcontrib><creatorcontrib>Lee, Sunhee</creatorcontrib><creatorcontrib>Frothingham, Richard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and vaccine immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hart, Bryan E</au><au>Asrican, Rose</au><au>Lim, So-Yon</au><au>Sixsmith, Jaimie D</au><au>Lukose, Regy</au><au>Souther, Sommer J R</au><au>Rayasam, Swati D G</au><au>Saelens, Joseph W</au><au>Chen, Ching-Ju</au><au>Seay, Sarah A</au><au>Berney-Meyer, Linda</au><au>Magtanong, Leslie</au><au>Vermeul, Kim</au><au>Pajanirassa, Priyadharshini</au><au>Jimenez, Amanda E</au><au>Ng, Tony W</au><au>Tobin, David M</au><au>Porcelli, Steven A</au><au>Larsen, Michelle H</au><au>Schmitz, Joern E</au><au>Haynes, Barton F</au><au>Jacobs, Jr, William R</au><au>Lee, Sunhee</au><au>Frothingham, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors</atitle><jtitle>Clinical and vaccine immunology</jtitle><addtitle>Clin Vaccine Immunol</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>22</volume><issue>7</issue><spage>726</spage><epage>741</epage><pages>726-741</pages><issn>1556-6811</issn><issn>1556-679X</issn><eissn>1556-679X</eissn><abstract>The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing consistent insert expression has encountered challenges in stability. Here, we describe a method for the development of large recombinant BCG accession lots which stably express the lentiviral antigens, human immunodeficiency virus (HIV) gp120 and simian immunodeficiency virus (SIV) Gag, using selectable leucine auxotrophic complementation. Successful establishment of vaccine stability stems from stringent quality control criteria which not only screen for highly stable complemented BCG ΔleuCD transformants but also thoroughly characterize postproduction quality. These parameters include consistent production of correctly sized antigen, retention of sequence-pure plasmid DNA, freeze-thaw recovery, enumeration of CFU, and assessment of cellular aggregates. Importantly, these quality assurance procedures were indicative of overall vaccine stability, were predictive for successful antigen expression in subsequent passaging both in vitro and in vivo, and correlated with induction of immune responses in murine models. This study has yielded a quality-controlled BCG ΔleuCD vaccine expressing HIV gp120 that retained stable full-length expression after 10(24)-fold amplification in vitro and following 60 days of growth in mice. A second vaccine lot expressed full-length SIV Gag for >10(68)-fold amplification in vitro and induced potent antigen-specific T cell populations in vaccinated mice. Production of large, well-defined recombinant BCG ΔleuCD lots can allow confidence that vaccine materials for immunogenicity and protection studies are not negatively affected by instability or differences between freshly grown production batches.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>25924766</pmid><doi>10.1128/CVI.00075-15</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1556-6811 |
ispartof | Clinical and vaccine immunology, 2015-07, Vol.22 (7), p.726-741 |
issn | 1556-6811 1556-679X 1556-679X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4478521 |
source | American Society for Microbiology; MEDLINE; PubMed Central; Alma/SFX Local Collection |
subjects | AIDS Vaccines - genetics AIDS Vaccines - immunology Animals Antigens, Viral - biosynthesis Antigens, Viral - genetics Drug Carriers Gene Products, gag - biosynthesis Gene Products, gag - genetics Genetic Vectors Genomic Instability HIV Envelope Protein gp120 - biosynthesis HIV Envelope Protein gp120 - genetics Human immunodeficiency virus Mice, Inbred C57BL Mycobacterium bovis Mycobacterium bovis - genetics SAIDS Vaccines - genetics SAIDS Vaccines - immunology Simian immunodeficiency virus T-Lymphocytes - immunology Vaccines |
title | Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A27%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stable%20Expression%20of%20Lentiviral%20Antigens%20by%20Quality-Controlled%20Recombinant%20Mycobacterium%20bovis%20BCG%20Vectors&rft.jtitle=Clinical%20and%20vaccine%20immunology&rft.au=Hart,%20Bryan%20E&rft.date=2015-07-01&rft.volume=22&rft.issue=7&rft.spage=726&rft.epage=741&rft.pages=726-741&rft.issn=1556-6811&rft.eissn=1556-679X&rft_id=info:doi/10.1128/CVI.00075-15&rft_dat=%3Cproquest_pubme%3E1701493795%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1691287070&rft_id=info:pmid/25924766&rfr_iscdi=true |